论文部分内容阅读
目的探讨沙美特罗替卡松粉吸入剂治疗轻中度支气管哮喘的临床疗效。方法选取原平市第一人民医院2010年9月—2016年9月收治的支气管哮喘患者100例,随机分为对照组和试验组,各50例。患者入院后均给予常规对症治疗,对照组患者给予布地奈德粉剂治疗,试验组患者给予沙美特罗替卡松粉吸入剂治疗,两组患者均持续治疗3个月。比较两组患者的临床疗效,咳嗽、胸闷、肺部哮鸣音、喘息消失时间及住院时间,并观察患者不良反应发生情况。结果试验组患者治疗总有效率高于对照组(P<0.05)。试验组患者咳嗽、胸闷、肺部哮鸣音、喘息消失时间及住院时间短于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论采用沙美特罗替卡松粉吸入剂治疗轻中度支气管哮喘的临床疗效确切,可有效改善患者的临床症状,缩短住院时间,安全可靠。
Objective To investigate the clinical efficacy of salmeterol and fluticasone powder inhaler in the treatment of mild to moderate bronchial asthma. Methods 100 patients with bronchial asthma admitted to the First People’s Hospital of Yuanping City from September 2010 to September 2016 were randomly divided into control group and experimental group, 50 cases each. Patients were given conventional symptomatic treatment after admission, the control group patients treated with budesonide powder treatment, patients in the test group were treated with salmeterol and fluticasone powder inhaler, two groups of patients were treated for 3 months. The clinical efficacy, cough, chest tightness, lung wheeze, wheezing disappearance time and hospital stay were compared between the two groups, and the incidence of adverse reactions was observed. Results The total effective rate of treatment in trial group was higher than that in control group (P <0.05). The cough, chest tightness, lung wheeze, wheezing disappearing time and hospital stay in trial group were shorter than those in control group (P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion The clinical efficacy of salmeterol and fluticasone powder inhalation for the treatment of mild to moderate bronchial asthma is definite, which can effectively improve the clinical symptoms, shorten the hospital stay and be safe and reliable.